Mareana, Inc.

Startup
Summarized by Halo AI

Mareana is a software company that provides AI-powered manufacturing intelligence and data management solutions for the pharmaceutical and biotechnology sectors, helping firms optimize production, accelerate batch releases, and ensure compliance.

Founded & HQ
Princeton, NJ, USA
Company size
51-200 employees
Funding
~$890K
Activity highlights
Named a Gartner Cool Vendor in AI for clinical and manufacturing value in the pharmaceutical and biotechnology sectors.

Mareana is an AI-powered software company that provides a manufacturing intelligence platform specifically designed for the pharmaceutical, biotechnology, and industrial manufacturing industries. The platform integrates fragmented data from various systems, including legacy paper records, into a unified, GxP-compliant environment. By leveraging artificial intelligence, natural language processing, and predictive analytics, the company’s solutions enable manufacturers to digitize workflows, automate batch record reviews, and gain real-time insights. Their technology is built to handle 21 CFR Part 11 and EU Annex 11 requirements, effectively transforming complex, manual manufacturing processes into streamlined, data-driven operations. Key products in their portfolio include solutions for Continued Process Verification (CPV), Chemistry, Manufacturing, and Controls (CMC), and Value Stream Mapping (VSM).

These capabilities are critical for customers looking to accelerate batch release cycles, reduce errors, and ensure consistent regulatory compliance. By modernizing data management, Mareana helps manufacturers anticipate quality deviations, optimize production yields, and minimize overtime costs. The company has demonstrated significant financial impact for clients, including delivering substantial annual cost savings and yield improvements for global pharmaceutical firms. Recognized as a Cool Vendor in AI by Gartner, Mareana continues to support organizations in mitigating supply chain risks and achieving operational excellence, allowing scientific teams to focus on core drug development rather than manual data extraction.

AI summary generated on Jun 22, 2026
OpenAlexOpenAlex

For general inquiries

PO
Paul Oberle
Business Development
Is this page yours? Boost its visibility
List technologies, facilities, services, or grant collaboration opportunities.

Looking for

Sponsored researchCo-developmentLicensingPilot or trial engagement

Key links

Halo home
Partner smarter. Move faster.
Get new partnering requests
delivered to your inbox.